Matinas BioPharma | Investor Presentation Deck | 29 slides · page 14 of 29
The slide highlights both the clinical urgency (toxicity, resistance) and the commercial potential (orphan disease status).
Pitch deck · problem_statement · frame_problem · dense density
Slide locked Sign in to view
Slide schematic 5/5
disclaimer 1/1 list 3/3 title 1/1
Components 5
disclaimer bullet bullet bullet headline
Tools 2
Problem Statement Canvas slide · 80%
High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)
Storytelling: primary demands slide · 60%Patients suffering from IA with little or no treatment options among the highest unmet medical need with approximately 3,000-5,000 cases per year (U.S. only).
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.